Last updated: February 27, 2026
What is the excipient profile for SUNMARK 12 HOUR ALLERGY RELIEF?
SUNMARK 12 HOUR ALLERGY RELIEF contains active ingredients typically including loratadine and pseudoephedrine. The excipient composition ensures stability, bioavailability, and patient compliance. While the exact formulation details are proprietary, common excipients in extended-release allergy formulations include:
- Fillers: Microcrystalline cellulose, lactose, starch.
- Binders: Hydroxypropyl methylcellulose (HPMC), povidone.
- Disintegrants: Croscarmellose sodium.
- Lubricants: Magnesium stearate, stearic acid.
- Coatings: Opadry or Eudragit-based polymers for controlled release.
The excipient selection focuses on maintaining the extended-release profile over 12 hours, minimizing gastrointestinal irritation, and ensuring stability under various storage conditions.
How does excipient strategy influence formulation performance?
An effective excipient strategy enhances drug stability, controls release kinetics, and improves binary compatibility with active pharmaceutical ingredients (APIs). For SUNMARK:
- Extended-release matrix: Utilizes hydrophilic polymers (e.g., HPMC) to control drug release over 12 hours, maintaining consistent plasma levels.
- Disintegration control: Cross-linked cellulose derivatives slow disintegration, reducing dosing frequency.
- Minimizing irritation: Non-ionic, inert excipients such as lactose and microcrystalline cellulose avoid gastrointestinal discomfort.
- Manufacturability: Optimized excipients facilitate scalable, cost-efficient manufacturing with consistent quality.
What are the commercial advantages of a tailored excipient approach?
A strategic excipient selection reduces manufacturing costs, improves product stability, and extends shelf life. It also allows for differentiation through formulation attributes such as:
- Enhanced bioavailability: Optimized excipients improve API absorption.
- Extended shelf life: Stabilizers prevent premature degradation, especially crucial in over-the-counter (OTC) markets.
- Formulation flexibility: Compatibility with various packaging formats (blister packs, bottles) broadens distribution channels.
- Regulatory compliance: Use of excipients with established safety profiles streamlines approval processes; the FDA and EMA maintain lists of acceptable excipients for OTC products.
What are current market trends influencing excipient strategies?
Key trends shaping excipient strategy include:
- Shift toward natural excipients: Increased demand for plant-based, non-GMO options reduces reliance on synthetic excipients.
- Regulatory scrutiny: Heightened focus on excipient safety, particularly in pediatric and vulnerable populations.
- Sustainability initiatives: Use of biodegradable and environmentally friendly excipients aligns with eco-conscious manufacturing.
- Patient-centric formulations: Efforts to improve palatability and reduce gastrointestinal side effects inform excipient choices.
How do regulatory frameworks impact excipient selection?
The U.S. FDA and European Medicines Agency (EMA) provide lists of approved excipients. For OTC products like SUNMARK:
- The excipients used must be on the approved lists for active ingredients and excipient combinations.
- Labeling must disclose all excipients, their quantities, and purposes.
- Extensive documentation demonstrating safety and compatibility is required for excipients introduced into the formulation.
What are the R&D and commercial opportunities?
Opportunities include:
- Innovating with novel excipients: Developing proprietary, extended-release polymers can differentiate products.
- Formulation improvements: Adding flavor-masking agents or texture enhancers to improve patient adherence.
- Sustainable excipient sourcing: Positioning as eco-friendly can appeal to health-conscious consumers.
- Intellectual property rights: Patentable excipient combinations or novel release mechanisms offer exclusivity.
Summary of Key Data
| Aspect |
Details |
| Active ingredients |
Loratadine, pseudoephedrine |
| Common excipients |
Microcrystalline cellulose, HPMC, lactose, croscarmellose sodium, magnesium stearate |
| Release mechanism |
Hydrophilic matrix controlling 12-hour release |
| Regulatory compliance |
FDA and EMA approved excipients |
| Market trend |
Natural, sustainable, patient-friendly excipients |
Key Takeaways
- Excipient selection directly impacts drug stability, release kinetics, and patient experience.
- Tailored excipient strategies enable cost-effective manufacturing, regulatory approval, and product differentiation.
- Growing emphasis on natural, eco-friendly, and safety-profile excipients aligns with market demand.
- Patent opportunities exist in novel excipient combinations and controlled-release mechanisms.
- Regulatory frameworks are increasingly stringent, necessitating thorough documentation and compliance.
FAQs
1. Can excipient modifications extend SUNMARK’s shelf life?
Yes. Incorporating antioxidants or stabilizers can improve API stability and extend shelf life.
2. Are there specific excipients preferred in OTC allergy medications?
Yes. Excipients with proven safety profiles, minimal gastrointestinal irritation, and compatibility with active ingredients are favored.
3. How do excipients influence bioavailability in extended-release formulations?
They control drug release rate, ensuring consistent plasma levels and minimizing peak-trough fluctuations.
4. Are natural excipients as effective as synthetic ones in extended-release formulations?
In some cases. Natural excipients can offer comparable performance but may pose challenges in consistency and scalability.
5. How do regulatory bodies restrict excipient use?
Through approved excipient lists, maximum allowable quantities, and safety data requirements, regulators ensure safety and efficacy.
References:
- U.S. Food and Drug Administration. (2022). Inactive Ingredients Database.
- European Medicines Agency. (2021). Guideline on excipients in pharmaceutical products.
- Aulton, M. E., & Taylor, K. (2013). Pharmaceutics: The Science of Dosage Form Design.
- Moore, J. A., & Kelly, K. (2019). Advanced formulations for extended-release drugs. International Journal of Pharmaceutics.
